Company Filing History:
Years Active: 2023-2025
Title: Innovations of Daniel Braas in RNAi Technology
Introduction
Daniel Braas is an accomplished inventor based in Madison, WI (US). He has made significant contributions to the field of biotechnology, particularly in the development of RNA interference (RNAi) agents. With a total of two patents to his name, Braas is recognized for his innovative approaches to gene expression inhibition.
Latest Patents
Braas's latest patents focus on RNAi agents designed to inhibit the expression of xanthine dehydrogenase (XDH). These agents, which include double-stranded RNAi components, are capable of targeting the XDH gene expression effectively. The patents also detail pharmaceutical compositions that incorporate these RNAi agents, along with methods for their use. Notably, the XDH RNAi agents can be conjugated to targeting ligands, enhancing their delivery to specific cells, including hepatocytes. This innovative delivery method allows for the in vivo inhibition of XDH gene expression, which is crucial in treating diseases such as gout and hyperuricemia.
Career Highlights
Daniel Braas is currently associated with Arrowhead Pharmaceuticals, Inc., where he continues to advance his research in RNAi technology. His work has positioned him as a key figure in the development of therapeutic solutions that address critical health issues related to XDH gene expression.
Collaborations
Braas collaborates with notable colleagues, including Anthony Nicholas and Tao Pei, who contribute to the innovative research environment at Arrowhead Pharmaceuticals, Inc. Their combined expertise fosters a collaborative atmosphere that enhances the potential for groundbreaking discoveries.
Conclusion
Daniel Braas's contributions to RNAi technology exemplify the impact of innovative thinking in biotechnology. His patents and ongoing research hold promise for advancing treatments for diseases linked to XDH gene expression.